Carboprost tromethamine
Carboprost Tromethamine, Hemabate (carboprost tromethamine) is a small molecule pharmaceutical. Carboprost tromethamine was first approved as Hemabate on 1982-01-01. It is used to treat cystitis, fetal death, incomplete abortion, and postpartum hemorrhage in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Carboprost tromethamine, Hemabate (discontinued: Carboprost tromethamine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carboprost tromethamine | ANDA | 2024-09-23 |
| hemabate | New Drug Application | 2022-01-10 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | 5 | 6 |
| Postpartum hemorrhage | D006473 | — | O72 | — | — | — | 1 | 4 | 5 |
| Uterine inertia | D014593 | EFO_1001863 | O62.2 | — | — | — | 2 | 1 | 3 |
| Cesarean section | D002585 | — | — | 1 | — | — | 1 | — | 2 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | 1 | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 1 | — | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female genital diseases | D005831 | EFO_0009549 | N85 | 1 | — | — | — | — | 1 |
| Leiomyoma | D007889 | HP_0000131 | D25 | 1 | — | — | — | — | 1 |
| Myofibroma | D047708 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystocia | D004420 | EFO_1000911 | O66.9 | — | — | — | — | 2 | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carboprost tromethamine |
| INN | — |
| Description | Carboprost is prostaglandin F2alpha in which the hydrogen at position 15 is substituted by methyl (S configuration). It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy. It has a role as an oxytocic and an abortifacient. It is functionally related to a prostaglandin F2alpha. It is a conjugate acid of a carboprost(1-). |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC[C@](C)(O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O.NC(CO)(CO)CO |
Identifiers
| PDB | — |
| CAS-ID | 35700-23-3 |
| RxCUI | 2051 |
| ChEMBL ID | CHEMBL1237105 |
| ChEBI ID | — |
| PubChem CID | 5281075 |
| DrugBank | DB00429 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 215 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
519 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use